18 and older, any sex, with Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Primary· up to 14.6 months
DCR was defined as the best overall response of complete response (CR), partial response (PR), or stable disease (SD). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diam
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
21.2
10.7 – 37.8
Cohort 2: Lungs-SCC
0.0
0.0 – 49.0
Cohort 3: Esophagus-SCC
0.0
0.0 – 79.3
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Secondary· From the first administration of study drug up to 30 days follow-up (up to 14.6 months)
An adverse event (AE) was defined as any unfavorable sign and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of the study drug, whether or not related to study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose (including after informed consent was signed and prior to dosing) that resulted in death, was life-threatening (participant was at immediate risk of death from event), required in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospi
Participants with TEAEs
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
37
Cohort 2: Lungs-SCC
5
Cohort 3: Esophagus-SCC
3
Participants with SAEs
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
18
Cohort 2: Lungs-SCC
2
Cohort 3: Esophagus-SCC
3
Number of Participants With Treatment-emergent Adverse Events by Severity: Clinical Terminology Categories for Adverse Events (CTCAE) Grading ScaleSecondary· From the first administration of study drug up to 30 days follow-up (up to 14.6 months)
AE:Any unfavorable sign and unintended sign,symptom, or disease temporarily associated with use of study drug, whether or not related to it. SAE:Any untoward medical occurrence that occurs at any dose (after informed consent was signed, prior dosing) that resulted in death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and important medical events. TEAE:Any AE with onset or worsening of existing condition on or after first dose through 30 days following last dose of stu
Mild (Grade 1)
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
3
Cohort 2: Lungs-SCC
0
Cohort 3: Esophagus-SCC
0
Moderate (Grade 2)
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
9
Cohort 2: Lungs-SCC
1
Cohort 3: Esophagus-SCC
0
Severe (Grade 3)
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
21
Cohort 2: Lungs-SCC
4
Cohort 3: Esophagus-SCC
3
Life Threatening (Grade 4)
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
3
Cohort 2: Lungs-SCC
0
Cohort 3: Esophagus-SCC
0
Fatal (Grade 5)
Group
Value
95% CI
Cohort 1: Head and Neck-SCC
1
Cohort 2: Lungs-SCC
0
Cohort 3: Esophagus-SCC
0
Adverse events — posted to ClinicalTrials.gov
Time frame: From the first administration of study drug up to 30 days after participant's last visit (up to 14.6 months).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Squamous Cell Carcinoma
Currently open trials in the same condition.
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca
· Phase 2
· recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
· Phase 2
· recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
· Phase 2
· recruiting
NCT07095608 — Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
· NA
· recruiting
NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies
· recruiting
Other Karyopharm Therapeutics Inc trials
Trials by the same sponsor.
NCT04854434 — A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previo
· Phase 2
· terminated
NCT04768881 — Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
· Phase 2
· terminated
NCT04421378 — A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
· Phase 1, PHASE2
· terminated
NCT04355676 — Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COV
· Phase 2
· withdrawn
NCT04349098 — Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karyopharm Therapeutics Inc
Last refreshed: 26 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02213133.